Cruise ship captain dies during 19-day voyage — passengers told over PA announcement
The captain of a major cruise liner has died during an almost month-long voyage around Asia.
Michele Bartolomei was captaining Princess Cruises' the Diamond Princess when he died suddenly on May 19 following a medical emergency.
The ship was on a 19-day Southern Islands Explorer voyage to locations including Japan and Korea when passengers and crew learned of the heartbreaking news over a PA announcement.
The ship was docked at Keelung, Taiwan at the time.
According to Nine News, a letter, which has been shared online, was also delivered to passengers' cabins with the sad update.
'It is with profound sadness that we share the news of the passing of Captain Michele Bartolomei, who died on-board Diamond Princess earlier of a sudden medical emergency,' it said.
3 Michele Bartolomei died after a medical emergency on May 19.
Princess Cruises / Facebook
'Our hearts are with Captain Bartolomei's family during this incredibly difficult time.'
It added that the Italian captain was a 'respected leader with 'decades of service at sea'.
According to Bartolomei's LinkedIn, he was approaching 30 years with the cruise liner.
'Captain with Princess cruises, working for this great company since August 1995, just over 25 years,' his profile reads.
Captain Salvatore Macera took command of the Diamond Princess ship as it continued its journey.
3 Bartolomei was approaching 30 years with the cruise liner.
Princess Cruises / Facebook
'Please be assured that our commitment to your safety and the smooth operation of this voyage remains our utmost priority,' Princess continued in the letter.
'Our highly experienced and professional bridge team is fully capable and will ensure the remainder of our journey continues as planned.'
Passengers reported being woken up in the early hours by an announcement asking the medical team to report to the medical centre, Nine News reported.
3 Passengers and crew learned of the heartbreaking news over a PA announcement.
Faizan – stock.adobe.com
Bartolomei lived in Canada and studied at nautical schools in Italy.
Many have taken to social media to express their condolences to Bartolomei's family.
'Heart breaking news. I am so sorry for his family and also for the staff and crew members on that ship,' one person wrote on TikTok.
'Thoughts to his family. I worked with his wife on princess back in the day. So very tragic for this family,' another added.
News.com.au has contacted Princess Cruises for comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
ZoomCare Opens New Clinic in Happy Valley
The company will host an Open House for the community on Jun. 13 PORTLAND, Ore., June 10, 2025 /PRNewswire/ -- ZoomCare, a network of neighborhood clinics serving a wide variety of healthcare needs, today announced the opening of a new clinic to serve the community of Happy Valley. The new clinic is located at 17155 SE Sunnyside Road, Suite #160 in the Happy Valley Crossroads Shopping Center. The clinic will be open seven days a week. Staffed with board-certified providers who cater to a broad range of illnesses and injuries, the Happy Valley clinic will also include preventive care services. The location features five exam rooms and offers on-site labs and prescriptions, allowing patients to leave with medications in hand. Since 2006, ZoomCare has been known for its patient experience, which is focused on compassion, quality, and efficiency. "ZoomCare believes you shouldn't have to travel far to receive excellent care," said Jeff Fee, Chief Executive Officer of ZoomCare. "We are thrilled to join the Happy Valley community. Opening this new location aligns perfectly with our mission to make healthcare easy and accessible for everyone." The company will celebrate the new clinic opening with an Open House event on Friday, Jun. 13, from 11 a.m. - 2 p.m. The Open House is open to the public and will offer free specialty coffee drinks and Italian sodas, fun giveaways, and a chance to meet the provider team and see the new clinic space. "This Open House is an excellent opportunity for our providers and clinic staff to get to know the people of Happy Valley," said Jennifer Alemany, Director of Clinical Operations in Portland. "We hope folks will come by, meet our team, and learn more about how ZoomCare can help with their healthcare needs now and in the future!" ZoomCare accepts Medicare and Medicare Advantage at all of its 47 locations in Oregon and Washington. Using Medicare-certified software platform Athenahealth, ZoomCare can access and share electronic health records with other providers and health systems. This certified software platform also lets ZoomCare establish partnerships with large health systems and insurance plans to increase patient access to primary, urgent, emergency, and specialty care. About ZoomCareZoomCare's vision is to make healthcare easy. Founded in 2006 in Portland, Oregon, ZoomCare operates more than 47 urgent, primary, emergency care, and specialty locations throughout Oregon and Washington. With conveniently located neighborhood clinics, plus evening and weekend hours, ZoomCare is committed to providing better access to healthcare and delivering evidence-based care with kindness at every visit. For more information, visit Follow ZoomCare on Facebook, Instagram, LinkedIn, and X. Media ContactAmanda Gibbs Director of Communications agibbs@ View original content to download multimedia: SOURCE ZoomCare
Yahoo
a day ago
- Yahoo
Newel Health obtains EU MDR for blood pressure management platform
Amid the growing prevalence of hypertension in the EU, Italian health tech Newel Health has secured a CE mark for its Amicomed platform under the EU's Medical Device Regulation (EU MDR), enabling it to support the management of high blood pressure. Compatible with blood pressure monitors including Apple Health and Google Fit, the smartphone app-based platform captures structured blood pressure data and translates it into 'clinically meaningful' insights, Newel Health stated, and offers personalised feedback towards high blood pressure management based on real-world data. The platform's features include medication reminders to improve adherence, and personalised lifestyle and dietary recommendations based on a user's clinical profile. The capabilities are supported by Amicomed's architecture. Developed by Newel Health, the proprietary platform uses artificial intelligence (AI)-based predictive models to improve behavioural segmentation, sustain engagement, and adapt interventions based on an individual's profile. A 2023 report by GlobalData forecasts that AI platforms in healthcare will reach a valuation of $18.8bn by 2027. Newel Health CEO, Ervin Ukaj commented: "We designed Amicomed to offer a digital therapy that fits into people's everyday lives, supporting them, day by day, in managing hypertension. "The MDR certification confirms the strength of our platform and the reliability of our regulatory approach.' Ukaj added that Newel intends to pursue 'scalable growth' by seeking further partnerships with public and private healthcare stakeholders. Systemic hypertension is a key risk factor for chronic disease burden, and a known precursor for cardiovascular diseases (CVDs) including atherosclerotic cardiovascular disease, with research indicating that hypertension in the EU is on the rise. A European Commission (EC) survey from 2019 found that 22% of individuals aged 15 and above reported having received a high blood pressure diagnosis from a medical professional, while a 2023 report by the World Health Organization (WHO) estimates that the number of adults with hypertension in the European region and the Americas rose from 302 million in 1990 to 427 million in 2019 – reflecting a 41% rise. All medical device manufacturers marketing products in the EU must fall in line with the dictates of the EU MDR regulation by 2028. Introduced in 2017 and coming into its 'first phase' of effect in 2021, the EU MDR is promulgated as a means to centralise competencies at the EU level. While well-intentioned, some observers have deemed the regulation's roll out a 'disaster', with concerns around a perceived lack of clarity, and the regulation's overall scope and complexity – factors that have proven particularly challenging for companies with existing device on the European market. "Newel Health obtains EU MDR for blood pressure management platform" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Newel Health obtains EU MDR for blood pressure management platform
Amid the growing prevalence of hypertension in the EU, Italian health tech Newel Health has secured a CE mark for its Amicomed platform under the EU's Medical Device Regulation (EU MDR), enabling it to support the management of high blood pressure. Compatible with blood pressure monitors including Apple Health and Google Fit, the smartphone app-based platform captures structured blood pressure data and translates it into 'clinically meaningful' insights, Newel Health stated, and offers personalised feedback towards high blood pressure management based on real-world data. The platform's features include medication reminders to improve adherence, and personalised lifestyle and dietary recommendations based on a user's clinical profile. The capabilities are supported by Amicomed's architecture. Developed by Newel Health, the proprietary platform uses artificial intelligence (AI)-based predictive models to improve behavioural segmentation, sustain engagement, and adapt interventions based on an individual's profile. A 2023 report by GlobalData forecasts that AI platforms in healthcare will reach a valuation of $18.8bn by 2027. Newel Health CEO, Ervin Ukaj commented: "We designed Amicomed to offer a digital therapy that fits into people's everyday lives, supporting them, day by day, in managing hypertension. "The MDR certification confirms the strength of our platform and the reliability of our regulatory approach.' Ukaj added that Newel intends to pursue 'scalable growth' by seeking further partnerships with public and private healthcare stakeholders. Systemic hypertension is a key risk factor for chronic disease burden, and a known precursor for cardiovascular diseases (CVDs) including atherosclerotic cardiovascular disease, with research indicating that hypertension in the EU is on the rise. A European Commission (EC) survey from 2019 found that 22% of individuals aged 15 and above reported having received a high blood pressure diagnosis from a medical professional, while a 2023 report by the World Health Organization (WHO) estimates that the number of adults with hypertension in the European region and the Americas rose from 302 million in 1990 to 427 million in 2019 – reflecting a 41% rise. All medical device manufacturers marketing products in the EU must fall in line with the dictates of the EU MDR regulation by 2028. Introduced in 2017 and coming into its 'first phase' of effect in 2021, the EU MDR is promulgated as a means to centralise competencies at the EU level. While well-intentioned, some observers have deemed the regulation's roll out a 'disaster', with concerns around a perceived lack of clarity, and the regulation's overall scope and complexity – factors that have proven particularly challenging for companies with existing device on the European market. "Newel Health obtains EU MDR for blood pressure management platform" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
